FDA extends reproxalap review to March 2026 after Aldeyra submits major amendment
Aldeyra Therapeutics (NASDAQ:ALDX) said the U.S. Food and Drug Administration has extended the PDUFA target action date for its reproxalap New Drug Application (NDA) for dry eye disease to March 16, 2026, adding roughly three months to the original timeline.










